Enlivex Therapeutics Ltd
NASDAQ:ENLV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Enlivex Therapeutics Ltd
Change in Working Capital
Enlivex Therapeutics Ltd
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Change in Working Capital
$815k
|
CAGR 3-Years
1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Change in Working Capital
-$13.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-6%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Change in Working Capital
-$27.9m
|
CAGR 3-Years
-64%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Change in Working Capital
$1.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
N
|
Neurosense Therapeutics Ltd
NASDAQ:NRSN
|
Change in Working Capital
$1.3m
|
CAGR 3-Years
23%
|
CAGR 5-Years
81%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Change in Working Capital
$3.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
Enlivex Therapeutics Ltd
Glance View
Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
See Also
What is Enlivex Therapeutics Ltd's Change in Working Capital?
Change in Working Capital
815k
USD
Based on the financial report for Dec 31, 2025, Enlivex Therapeutics Ltd's Change in Working Capital amounts to 815k USD.
What is Enlivex Therapeutics Ltd's Change in Working Capital growth rate?
Change in Working Capital CAGR 3Y
1%
The average annual Change in Working Capital growth rates for Enlivex Therapeutics Ltd have been 1% over the past three years .
